Legal status by country
Is Albiglutide legal?
Written by Aaron CuhaReviewed Sep 2026
How Albiglutide is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Approved, product discontinued | Approved, product discontinued | Not registered | Not approved |
| Note | BLA 125431 approved 15 April 2014; Drugs@FDA marketing status Discontinued as of 11 September 2026. Not available. | EU marketing authorisation for Eperzan granted 20 March 2014 and withdrawn 29 October 2018 at the request of the holder, per the EMA record. Not available. | No current TGA registration located. | No Health Canada approval located. |
US FDA status: FDA approved 15 April 2014 (Tanzeum, BLA 125431) for glycaemic control in adults with type 2 diabetes. Drugs@FDA marketing status: Discontinued. EU authorisation (Eperzan) granted March 2014 and withdrawn 29 October 2018 at the holder's request.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.